Group 1 - The ACIP has overwhelmingly recommended that all flu vaccines should stop using thimerosal as a preservative, with a unanimous vote for specific populations including those under 18, pregnant women, and adults [1] - The committee strongly advocates for the adoption of single-dose vials of thimerosal-free flu vaccines to replace traditional multi-dose packaging [1] - Concerns were raised about the potential supply issues if multi-dose vials are completely abandoned, emphasizing the greater risk posed by the flu virus compared to the potential risks of thimerosal [1] Group 2 - Major pharmaceutical companies including GSK, Sanofi, AstraZeneca, and CSL Seqirus have completed the production of flu vaccines for the 2024-2025 season, which will be available in the U.S. market [2] - The stock prices of these four pharmaceutical giants have seen slight increases amid the ongoing debate over vaccine preservatives [2] - The controversy surrounding vaccine preservatives highlights the scientific debates in public health decisions and the influence of anti-vaccine movements on professional agendas [2]